BFS
CGTX icon

Bradley Foster & Sargent’s Cognition Therapeutics CGTX Stock Holding History

Bradley Foster & Sargent’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5K Hold
11,722
– – ﹤0.01% 535
2026
Q1 		$8.9K Hold
11,722
– – ﹤0.01% 516
2025
Q4 		$15.8K Hold
11,722
– – ﹤0.01% 527
2025
Q3 		$15.8K Hold
11,722
– – ﹤0.01% 536
2025
Q2 		$3.63K Hold
11,722
– – ﹤0.01% 536
2025
Q1 		$4.93K Buy
+11,722
New +$6.89K ﹤0.01% 455

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Bradley Foster & Sargent's CGTX Position: Q2 2026 in Review

Bradley Foster & Sargent held its Cognition Therapeutics (CGTX) position steady in Q2 2026 at 11,722 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #535.

Bradley Foster & Sargent first reported a position in CGTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $15.8K in Q4 2025. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Bradley Foster & Sargent held 11,722 shares of Cognition Therapeutics worth $13.5K as of Q2 2026.
  • Bradley Foster & Sargent left its Cognition Therapeutics share count unchanged in Q2 2026.
  • Cognition Therapeutics made up ﹤0.01% of Bradley Foster & Sargent's portfolio in Q2 2026, its #535 holding.
  • Bradley Foster & Sargent first reported a position in Cognition Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Bradley Foster & Sargent's Cognition Therapeutics position peaked at $15.8K in Q4 2025.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Bradley Foster & Sargent's 13F filing for Q2 2026, filed 14 Aug 2026.